TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18713232

Group type: EXPERIMENTAL
Intervention: Calcium dobesilate 1 g twice per day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15824342

Group type: EXPERIMENTAL
Intervention: High-resolution T2 reversed (T2R) MRI
Number of subjects: 15

Group type: COMPARATOR
Intervention: Normal volunteers (control group)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Disease controls (stroke or tumor subjects)
Number of subjects: 15
Study: 11840097

Group type: EXPERIMENTAL
Intervention: 20 mL 0.25% bupivacaine
Number of subjects: 44

Group type: COMPARATOR
Intervention: 20 mL 0.9% saline
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 44
Study: 10803112

Group type: EXPERIMENTAL
Intervention: Dyract (DY) with conventional polymerization (CP)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dyract (DY) with softstart-polymerization (SSP)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Hytac (HY) with conventional polymerization (CP)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Hytac (HY) with softstart-polymerization (SSP)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Hytac (HY) with both polymerization modes without preparation
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dyract (DY) with softstart-polymerization (SSP) without preparation
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dyract (DY) and Hytac (HY) with preparation
Number of subjects: 20
Study: 8771419

Group type: EXPERIMENTAL
Intervention: Wallstents
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Ultraflex stents
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Gianturco-Z stents
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: All stent types
Number of subjects: 87
Study: 1611832

Group type: EXPERIMENTAL
Intervention: Low glycaemic index diet
Number of subjects: 18

Group type: COMPARATOR
Intervention: High glycaemic index diet
Number of subjects: 18
Study: 6428513

Group type: EXPERIMENTAL
Intervention: Single channel cystometry
Number of subjects: 100

Group type: COMPARATOR
Intervention: Multichannel cystometry
Number of subjects: 100
Study: 31690794

Group type: EXPERIMENTAL
Intervention: OS-MRSA isolates
Number of subjects: 74

Group type: COMPARATOR
Intervention: MRSA isolates
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: All isolates
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: MDR isolates
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Sensitive isolates
Number of subjects: 74
Study: 29250843

Group type: EXPERIMENTAL
Intervention: Cinnamon powder capsules 1.5 g/day in 3 divided doses for 12 weeks
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 66
Study: 26054202

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) treatment
Number of subjects: 200

Group type: COMPARATOR
Intervention: Medication group (controlled ovarian hyperstimulation using Diane‐35, Decepepty, Gonadotrophin, human Chorionic Gonadotrophin)
Number of subjects: 200
Study: 23587135

Group type: EXPERIMENTAL
Intervention: TENS treatment (30 minutes simultaneous electrical stimulation of the posterior neck and the right Zusanli acupoint)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Simulator exposure (control condition)
Number of subjects: 15
Study: 21399959

Group type: EXPERIMENTAL
Intervention: ST(BFR) - Blood flow restriction for stimulated thigh
Number of subjects: 7

Group type: COMPARATOR
Intervention: NT(BFR) - Blood flow restriction for non-stimulated thigh
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Both ST(BFR) and NT(BFR)
Number of subjects: 7
Study: 19678948

Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg t.i.d.
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Weight-maintenance program
Number of subjects: 9
Study: 17432402

Group type: EXPERIMENTAL
Intervention: Filtek Z250
Number of subjects: 38

Group type: COMPARATOR
Intervention: CSE non‐etch
Number of subjects: 38

Group type: COMPARATOR
Intervention: CSE etch
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Durafill VS (microfilled composite)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Filtek Supreme (nanofilled composite)
Number of subjects: 38
Study: 15175561

Group type: EXPERIMENTAL
Intervention: Nifedipine capsules (2 x 10 mg doses given q8h for a total of three doses)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Nifedipine prolonged action tablets (20 mg doses given q12h for a total of two doses)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Nifedipine GITS tablet (60 mg single dose)
Number of subjects: 25
Study: 11579872

Group type: EXPERIMENTAL
Intervention: Insecticide-treated curtains
Number of subjects: 0
Study: 8470059

Group type: EXPERIMENTAL
Intervention: 50 U/kg of AT-III concentrate (Group A)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 100 U/kg of AT-III concentrate (Group B)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Heparin (small amounts detected in AT-III concentrates)
Number of subjects: 8
Study: 3956940

Group type: EXPERIMENTAL
Intervention: 10 mg of cisapride
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 4 mg of cisapride
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 12
Study: 31281181

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Folinic Acid (FA)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: L-thyroxine
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: FA + L-thyroxine
Number of subjects: 175
Study: 30260741

Group type: COMPARATOR
Intervention: Ozone therapy
Number of subjects: 36

Group type: COMPARATOR
Intervention: Laser photobiomodulation
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study: 27129871

Group type: EXPERIMENTAL
Intervention: MD+aPDT
Number of subjects: 67

Group type: COMPARATOR
Intervention: MD only
Number of subjects: 67
Study: 25006185

Group type: EXPERIMENTAL
Intervention: Regular NSAID use
Number of subjects: 160801

Group type: EXPERIMENTAL
Intervention: Selective cox‐2 inhibitors (e.g., celecoxib)
Number of subjects: 160801

Group type: EXPERIMENTAL
Intervention: Nonselective agents with cox‐2>cox‐1 inhibition (e.g., naproxen)
Number of subjects: 160801

Group type: EXPERIMENTAL
Intervention: Nonselective agents with cox‐1>cox‐2 inhibition (e.g., ibuprofen)
Number of subjects: 160801
Study: 23684823

Group type: EXPERIMENTAL
Intervention: 7-valent pneumococcal conjugate vaccine (PCV7)
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal polysaccharide vaccine (PPV23)
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: PCV7 plus PPV23
Number of subjects: 331

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 331
Study: 20442581

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 60
Study: 20208198

Group type: EXPERIMENTAL
Intervention: Culturally customized program (Esperanza y Vida)
Number of subjects: 847

Group type: COMPARATOR
Intervention: Diabetes education program (control)
Number of subjects: 847
Study: 16319505

Group type: EXPERIMENTAL
Intervention: Antiretroviral treatment
Number of subjects: 165

Group type: COMPARATOR
Intervention: No antiretroviral treatment
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: ASPD presence
Number of subjects: 165

Group type: COMPARATOR
Intervention: ASPD absence
Number of subjects: 165
Study: 14614414

Group type: EXPERIMENTAL
Intervention: Twin-block appliance treatment
Number of subjects: 174

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 174
Study: 10910424

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 32
Study: 8807727

Group type: EXPERIMENTAL
Intervention: Defibrotide
Number of subjects: 103
Study: 1461782

Group type: EXPERIMENTAL
Intervention: Vaccine containing the strains Edmonston‐Zagreb, Rubini and Wistar Ra 27/3
Number of subjects: 201

Group type: COMPARATOR
Intervention: Other types of trivalent measles-mumps-rubella vaccines (not specified)
Number of subjects: 201
Study: 3528718

Group type: EXPERIMENTAL
Intervention: Postoperative human albumin administration
Number of subjects: 161

Group type: COMPARATOR
Intervention: Control group (no human albumin therapy)
Number of subjects: 161
Study: 29266169

Group type: EXPERIMENTAL
Intervention: Curettage
Number of subjects: 256

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 256

Group type: COMPARATOR
Intervention: Curettage vs. Expectant management
Number of subjects: 256
Study: 27633174

Group type: EXPERIMENTAL
Intervention: Probiotic treatment (Lactobacillus casei Shirota)
Number of subjects: 417

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 417
Study: 24107227

Group type: EXPERIMENTAL
Intervention: Life-review group intervention
Number of subjects: 0
Study: 21733490

Group type: EXPERIMENTAL
Intervention: Quetiapine 1200 mg/d
Number of subjects: 131

Group type: COMPARATOR
Intervention: Quetiapine 800 mg/d
Number of subjects: 131
Study: 21921224

Group type: EXPERIMENTAL
Intervention: Raltegravir combined with tenofovir/emtricitabine
Number of subjects: 563

Group type: COMPARATOR
Intervention: Efavirenz combined with tenofovir/emtricitabine
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: Raltegravir
Number of subjects: 563

Group type: COMPARATOR
Intervention: Efavirenz
Number of subjects: 563
Study: 19836301

Group type: EXPERIMENTAL
Intervention: Congenital CMV infection
Number of subjects: 192

Group type: COMPARATOR
Intervention: Newborn hearing screening (NHS)
Number of subjects: 192
Study: 17047934

Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Scopolamine
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 15257749

Group type: EXPERIMENTAL
Intervention: 0.2% CHX pre-brushing rinse with SLS-containing dentifrice (Colgate Total)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 0.2% CHX pre-brushing rinse with SLS-containing dentifrice (Aquafresh Natural Whitening)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 0.2% CHX pre-brushing rinse with SLS-free dentifrice (Zendium)
Number of subjects: 35

Group type: COMPARATOR
Intervention: 0.2% CHX rinse only (control)
Number of subjects: 35
Study: 10717506

Group type: EXPERIMENTAL
Intervention: Racecadotril
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Loperamide
Number of subjects: 0
Study: 9350607

Group type: EXPERIMENTAL
Intervention: Vancomycin (5 mg/kg/day bid)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Teicoplanin (5 mg/kg/day once daily)
Number of subjects: 55
Study: 8462498

Group type: EXPERIMENTAL
Intervention: Internal attribution message
Number of subjects: 197

Group type: COMPARATOR
Intervention: External attribution message
Number of subjects: 197

Group type: COMPARATOR
Intervention: Information-only message
Number of subjects: 197
Study: 3929659

Group type: EXPERIMENTAL
Intervention: Eucapnic hypoxia (8% O2 in N2)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Eucapnic hyperpnea with dry air
Number of subjects: 15
Study: 29125700

Group type: EXPERIMENTAL
Intervention: Formulation C (2 × 25 mg)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Formulation D (2 × 12.5 mg)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Formulation E (2 × 12.5 mg)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Formulation C (1 × 25 mg) under fed conditions
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: All formulations
Number of subjects: 58
Study: 27137422

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy for antepartum depression (IPT-P)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Parenting education program (PEP)
Number of subjects: 75
Study: 25525278

Group type: EXPERIMENTAL
Intervention: Psychoeducation and systematic desensitization
Number of subjects: 42

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 42
Study: 22305026

Group type: EXPERIMENTAL
Intervention: 4 oz of cranberry juice daily
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: 8 oz of cranberry juice daily
Number of subjects: 176

Group type: COMPARATOR
Intervention: Placebo juice
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Cranberry juice
Number of subjects: 176

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176
Study: 20032170

Group type: EXPERIMENTAL
Intervention: Home blood pressure monitoring (at least weekly measurements)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 18655841

Group type: COMPARATOR
Intervention: FFIS 20microg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: FFIS 244microg
Number of subjects: 60

Group type: COMPARATOR
Intervention: FFIS 10, 20, 244microg
Number of subjects: 60
Study: 15797175

Group type: EXPERIMENTAL
Intervention: ANAM tasks measuring working memory
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: ANAM efficiency scores
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Discriminant function analysis
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: ANAM
Number of subjects: 16

Group type: COMPARATOR
Intervention: MMSE scores
Number of subjects: 16
Study: 12622932

Group type: EXPERIMENTAL
Intervention: GM-CSF (50 micro g) plus recombinant hepatitis B vaccine (10 micro g) injected intramuscularly at the same location
Number of subjects: 27

Group type: COMPARATOR
Intervention: HBIG (200 IU) plus recombinant hepatitis B vaccine (10 micro g) in different muscles
Number of subjects: 27
Study: 10517191

Group type: EXPERIMENTAL
Intervention: Beta antigen gene presence in GBS strains
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: C protein beta antigen gene PCR analysis
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Vaccine based on peptide antigens from beta antigen of C protein
Number of subjects: 163
Study: 7497555

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% with 1:200,000 epinephrine peritonsillar infiltration
Number of subjects: 43

Group type: COMPARATOR
Intervention: Bupivacaine 0.5% with 1:200,000 epinephrine spray
Number of subjects: 43

Group type: COMPARATOR
Intervention: Normal saline spray (placebo)
Number of subjects: 43
Study: 1645642

Group type: EXPERIMENTAL
Intervention: Log-rank test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gehan's generalization of the Wilcoxon test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modified Kolmogorov-Smirnov test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: VA Cooperative Study No. 90
Number of subjects: 0
Study: 6124803

Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Apomorphine (0.005 mg/kg)
Number of subjects: 15
Study: 31725748

Group type: EXPERIMENTAL
Intervention: Muscle depth measurement on ultrasound (bicep, forearm, thigh)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Nitrogen balance measurement (g/24h)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Serum C-reactive protein, urinary urea, 3-methylhistidine measurements
Number of subjects: 78
Study: 28608305

Group type: EXPERIMENTAL
Intervention: Preoperative radiochemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Direct explorative laparotomy
Number of subjects: 0
Study: 25331262

Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus salivarius UBL S22
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Synbiotic (Probiotic Lactobacillus salivarius UBL S22 + Prebiotic Fructo-oligosaccharide)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 24122871

Group type: EXPERIMENTAL
Intervention: Netupitant 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Netupitant 300 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Netupitant 450 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: [(14) C]‐netupitant 300 mg (ADME study)
Number of subjects: 0
Study: 22526050

Group type: EXPERIMENTAL
Intervention: Fast-track surgery
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 70
Study: 19766760

Group type: EXPERIMENTAL
Intervention: Pomegranate juice (240 ml/day)
Number of subjects: 289

Group type: COMPARATOR
Intervention: Control beverage
Number of subjects: 289
Study: 17076064

Group type: EXPERIMENTAL
Intervention: Energy model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Feature model
Number of subjects: 0
Study: 15346227

Group type: EXPERIMENTAL
Intervention: Resistance settings for LW males: 58.9, 63.8, 68.7, 73.7, 78.6 N; Peak 5 s PO RLF: 0.109 kg.kg(-1) BM; Mean 30 s PO RLF: 0.102 kg.kg(-1) BM.
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Resistance settings for HW males: 83.5, 88.4, 93.4, 98.2, 103.1 N; Peak 5 s PO RLF: 0.102 kg.kg(-1) BM; Mean 30 s PO RLF: 0.095 kg.kg(-1) BM.
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Resistance settings for LW females: 29.4, 34.3, 39.2, 44.1, 49.1 N; Peak 5 s PO RLF: 0.111 kg.kg(-1) BM; Mean 30 s PO RLF: 0.103 kg.kg(-1) BM.
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Resistance settings for HW females: 44.1, 49.1, 54.0, 58.6, 63.8 N; Peak 5 s PO RLF: 0.076 kg.kg(-1) BM; Mean 30 s PO RLF: 0.068 kg.kg(-1) BM.
Number of subjects: 31

Group type: COMPARATOR
Intervention: Concept II rowing machine; Peak 5 s PO significantly lower compared to the modified Gjessing rowing ergometer; Mean 30 s PO not significantly different.
Number of subjects: 31
Study: 11273914

Group type: EXPERIMENTAL
Intervention: Voluven
Number of subjects: 100

Group type: COMPARATOR
Intervention: HAES‐steril
Number of subjects: 100
Study: 9471921

Group type: EXPERIMENTAL
Intervention: Chronic exposure to carbon disulphide (CS2) at concentrations of 9.36‐23.4 mg/m3
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Chronic exposure to carbon disulphide (CS2)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Normal population (control group)
Number of subjects: 199
Study: 8216014

Group type: EXPERIMENTAL
Intervention: Dorzolamide (2%)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 3315594

Group type: EXPERIMENTAL
Intervention: Intravenous anisoylated plasminogen streptokinase activator complex (APSAC) 30U
Number of subjects: 82

Group type: COMPARATOR
Intervention: Heparin 5000U
Number of subjects: 82
Study: 29859180

Group type: EXPERIMENTAL
Intervention: Ballistic strength training 3 times per week for 6 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 30
Study: 25687927

Group type: EXPERIMENTAL
Intervention: Multicomponent home‐based rehabilitation program (ProMo)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 81
Study: 23935011

Group type: EXPERIMENTAL
Intervention: 4F‐PCC
Number of subjects: 202

Group type: COMPARATOR
Intervention: Plasma
Number of subjects: 202
Study: 21091220

Group type: EXPERIMENTAL
Intervention: Irbesartan/HCTZ 150/12.5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Valsartan/HCTZ 80/12.5 mg
Number of subjects: 0
Study: 18220941

Group type: EXPERIMENTAL
Intervention: Aggrenox (antiplatelet agent)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Magnesium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NXY (free radical trapping agent)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Albumin (neuroprotectant)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amphetamine (to aid motor recovery)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluoxetine (anti-depressant and anxiolytic)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (for prevention of deep vein thrombosis post-stroke)
Number of subjects: 0
Study: 15121566

Group type: EXPERIMENTAL
Intervention: Rofecoxib (50 mg daily, oral)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Magnesium sulfate (intravenous)
Number of subjects: 214
Study: 11434791

Group type: EXPERIMENTAL
Intervention: Primary care office intervention incorporating meal replacements
Number of subjects: 113

Group type: COMPARATOR
Intervention: Dietitian-led group intervention not using meal replacements
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Dietitian-led group intervention incorporating meal replacements
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: All groups with weight loss of 5% to 10%
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: All groups with weight loss of 10% or greater
Number of subjects: 113
Study: 9876475

Group type: EXPERIMENTAL
Intervention: High-dose steroid (prednisone or dexamethasone) during remission induction
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Chemotherapy-maintained remission
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Supplemental magnesium for hypomagnesemia
Number of subjects: 56

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 56
Study: 8205806

Group type: EXPERIMENTAL
Intervention: Screening intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 0
Study: 3191636

Group type: EXPERIMENTAL
Intervention: Low-frequency pulsing electromagnetic fields (PEMF) stimulation
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no PEMF stimulation)
Number of subjects: 32
Study: 15118845

Group type: EXPERIMENTAL
Intervention: MPI-routine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: MPI-attenuation
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: MPI-scatter
Number of subjects: 100
Study: 31188198

Group type: EXPERIMENTAL
Intervention: Preoperative ultrasound (US) assessment of regional lymph nodes
Number of subjects: 2859
Study: 31822885

Group type: EXPERIMENTAL
Intervention: Combination therapy (favipiravir and oseltamivir)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Oseltamivir monotherapy
Number of subjects: 168
Study: 31112384

Group type: EXPERIMENTAL
Intervention: Mometasone
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Tiotropium
Number of subjects: 295

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 295
Study: 28365220

Group type: EXPERIMENTAL
Intervention: Shoe with 0mm drop (D0)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Shoe with 6mm drop (D6)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Shoe with 10mm drop (D10)
Number of subjects: 59
Study: 25400284

Group type: EXPERIMENTAL
Intervention: Viagra (original) 100 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Edyfil (generic) 100 mg
Number of subjects: 0
Study: 23840361

Group type: EXPERIMENTAL
Intervention: Cocoa consumption (6 g/d) for two weeks
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Cocoa extract treatment in PBMCs
Number of subjects: 214